Skip to Content
New To Chronic Myeloid Leukemia? Get Information Today >>

Belinostat Disease Interactions

There are 5 disease interactions with belinostat:

Major

Belinostat (Includes Belinostat) ↔ Tumor Lysis Syndrome

Severe Potential Hazard, Moderate plausibility

Applies to: Tumor Lysis Syndrome

Tumor lysis syndrome has occurred in patients treated with belinostat. It is recommended to monitor patients with advanced stage disease and/or high tumor burden and take appropriate precautions.

Moderate

Belinostat (Includes Belinostat) ↔ Hematologic Toxicity

Moderate Potential Hazard, Moderate plausibility

Applies to: Thrombocytopenia, Anemia, Lymphocytopenia, Neutropenia

Belinostat can cause thrombocytopenia, leukopenia (neutropenia and lymphopenia), and/or anemia. It is recommended to monitor blood counts weekly during treatment, and modify dosage as necessary. It is recommended to monitor complete blood counts at baseline and weekly and to perform serum chemistry tests, including renal and hepatic functions prior to the start of the first dose of each cycle. Absolute neutrophil count (ANC) should be greater than or equal to 1.0 x 10 9/L and the platelet count should be greater than or equal to 50 x 10 9/L prior to the start of each cycle and prior to resuming treatment following toxicity. Discontinue belinostat in patients who have recurrent ANC nadirs less than 0.5 x 10 9/L and/or recurrent platelet count nadirs less than 25 x 10 9/L after two dosage reductions. Close monitoring is recommended.

Moderate

Belinostat (Includes Belinostat) ↔ Hepatic Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Belinostat is metabolized by the liver, primarily by hepatic UGT1A1. Hepatic impairment is expected to increase exposure to belinostat, which can result in fatal hepatotoxicity and liver function test abnormalities. Reduce the starting dose of belinostat to 750 mg/m2 in patients known to be homozygous for the UGT1A1*28 allele to minimize dose limiting toxicities. There is insufficient data to recommend a dose of belinostat in patients with moderate and severe hepatic impairment. It is recommended to monitor liver function tests before treatment and before the start of each cycle and to interrupt or adjust dosage until recovery, or permanently discontinue belinostat based on the severity of the hepatic toxicity. Care should be taken when using belinostat in these patients.

Moderate

Belinostat (Includes Belinostat) ↔ Infections

Moderate Potential Hazard, Moderate plausibility

Applies to: Infection - Bacterial/Fungal/Protozoal/Viral

Serious and sometimes fatal infections, including pneumonia and sepsis, have occurred with the use of belinostat. Do not administer belinostat to patients with an active infection. Close monitoring is recommended.

Moderate

Belinostat (Includes Belinostat) ↔ Renal Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Belinostat exposure is not altered in patients with creatinine clearance (CrCl) > 39 mL/min. There is insufficient data to recommend a dose of belinostat in patients with CrCl <= 39 mL/min. Care should be taken when using belinostat in these patients.

belinostat drug Interactions

There are 134 drug interactions with belinostat

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide